Hamlet Biopharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Hamlet Biopharma is a clinical-stage biotech advancing a novel oncology platform and repurposed immunology assets. Its lead candidate, Alpha1H, derived from the HAMLET complex, has shown promising efficacy in Phase II for non-muscle invasive bladder cancer (NMIBC). The company is also developing anakinra for recurrent urinary tract infections (rUTI) and severe bladder pain, having completed successful Phase II studies. Based in Lund, Sweden, Hamlet appears to be a publicly-traded, pre-revenue entity preparing for Phase III trials.

OncologyInfectious DiseaseUrology

Technology Platform

HAMLET/Alpha1H platform: A protein-lipid complex (alpha-lactalbumin + oleic acid) that selectively targets and kills tumor cells via apoptosis while sparing healthy tissue.

Opportunities

Alpha1H addresses a large, costly NMIBC market with high recurrence rates and significant unmet need for effective, non-toxic therapies.

The anakinra programs tap into the urgent global need for non-antibiotic treatments for rUTI and better options for chronic bladder pain, both underserved markets.

Risk Factors

The company faces significant clinical development risk in advancing its Phase II candidates to approval, and substantial financial risk as a pre-revenue entity dependent on raising capital.

Competitive and commercial risks loom, particularly in establishing a novel agent like Alpha1H against existing standards of care.

Competitive Landscape

In NMIBC, Alpha1H competes with intravesical chemotherapy (e.g., mitomycin C), BCG immunotherapy, and newer gene therapies. Its selective mechanism is differentiating. In rUTI, anakinra competes with chronic antibiotic use, emerging vaccines, and other immunomodulators. Its proven anti-inflammatory effect offers a unique value proposition.

More companies in Small Molecule Drugs →More companies in Sweden →